The use of methylphenidate among students: The future of enhancement?

Journal of Medical Ethics

Volumn 36, Issue 4, 2010, Pages 198-202

  Outram, Simon M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE; NOOTROPIC AGENT;

ARTICLE; ATTENTION; COGNITION; DRUG EFFECT; HUMAN; PSYCHOLOGICAL ASPECT; STUDENT;

ATTENTION; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; HUMANS; METHYLPHENIDATE; NOOTROPIC AGENTS; STUDENTS;

EID: 77956089219     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/jme.2009.034421     Document Type: Article

References (42)

1. Baylis F, Robert JS. The inevitability of genetic enhancement technologies. Bioethics 2004;18:1-26.
2. Cakic V. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. J Med Ethics 2009;35:611e15.
3. Chatterjee A. The promise and predicament of cosmetic neurology. J Med Ethics 2006;32:110e13.
4. Farah MJ, Illes J, Cook-Deegan R, et al. Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 2004;5:421e5.
5. Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitiveenhancing drugs by the healthy. Nature 2008;456:702e5.
6. Parens E. Authenticity and ambivalence. Hastings Cent Rep 2005;35:34e41.
7. Sahakian B, Morein-Zamir S. Professor's little helper. Nature 2007;450:1157e9.
8. Sandel MJ. The case against perfection. Atl Mon 2004;293:50e62.
9. Williams SJ, Martin P. Risks and benefits may turn out to be finely balanced. Nature 2009;457:532.
10. Nordmann A. If and then: a critique of speculative nanoethics. Nanoethics 2007;1:31e46.
11. Brown N. Hope against hypedaccountability in biopasts, presents and futures. Science Studies 2003;16:3e21.
12. Leonard BE, McCartan D, White J, et al. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004;19:151e80.
13. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127e52.
14. Vastag B. Pay attention: ritalin acts much like cocaine. JAMA 2001;286:905e6.
15. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001;21:121RC.
16. Normann C, Berger M. Neuroenhancement: status quo and perspectives. Eur Arch Psychiatry Clin Neurosci 2008;258:110e14.
17. Larriviere D, Williams MA, Rizzo M, et al. Responding to requests from adult patients for neuroenhancements: Guidance of the Ethics, Law and Humanities Committee. Neurology 2009;73:1406e12.
18. Mehta MA, Owen AM, Sahakian BJ, et al. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000;20:65RC.
19. Elliott R, Sahakian BJ, Matthews K, et al. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) 1997;131:196e206.
20. Koelega HS. Stimulant drugs and vigilance performance: a review. Pharmacology 1993;111:1e16.
21. Schermer M, Bolt I, de Jong R, et al. The future of psychopharmacological enhancements: expectations and policies. Neuroethics 2009;2:75e87.
22. Turner DC, Robbins TW, Clark L, et al. Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology (Berl) 2003;168:455.
23. Efron D, Jarman F. Side effects of methylphenidate and dexamphetamine in children with attention deficit. Pediatrics 1997;100:662e6.
24. Kooij JJS, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med 2004; 34:973e82.
25. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:456e63.
26. Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol 2009;23:194e205.
27. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001;68:611e27.
28. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the future national survey results on drug use, 1975-2007. Vol. II. College students and adults ages 19-45 (NIH Publication No. 08-6418B). Bethesda, MD: National Institute on Drug Abuse, 2008, Table 2-2.
29. White BP, Becker-Blease K, Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J Am Coll Health 2006;54:261e8.
30. Babcock Q, Byrne T. Student perceptions of methylphenidate abuse at a public liberal arts college. J Am Coll Health 2000;49:143e5.
31. Hall KM, Irwin MM, Bowman KA, et al. Illicit use of prescribed stimulant medication among college students. J Am Coll Health 2005;53:167e74.
32. Teter CJ, McCabe SE, Cranford JA, et al. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 2005;53:253e62.
33. Barrett SP, Darredeau C, Bordy LE, et al. Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry 2005;50:457e61.
34. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the future national survey results on drug use, 1975-2008. Vol. I. Secondary school students (NIH Publication No. 09-7402). Bethesda, MD: National Institute on Drug Abuse, 2008:143.
35. National Drug Intellegence Center National Drug Threat Assessment. 2009. http://www.usdoj.gov/ndic/pubs31/31379/index.htm (accessed 23 October 2009) - Appendix B. Table B1.
36. Hedgecoe A, Martin P. The drugs don't work: expectations and the shaping of pharmacogenetics. Soc Stud Sci 2003;33:327e64.
37. Advokat CD, Guidry D, Martino L. Licit and illicit use of medications for attentiondeficit hyperactivity disorder in undergraduate college students. J Am Coll Health 2008;56:601e6.
38. Rose SPR. Science and society: 'Smart Drugs': do they work? Are they ethical? Will they be legal? Nat Rev Neurosci 2002;3:975e9.
39. Frazzetto G, Keenan S, Singh I. 'I Bambini e le Droghe': the right to ritalin vs the right to childhood in Italy. BioSocieties 2007;2:393e412.
40. Hawthorne S. ADHD drugs: values that drive the debates and decisions. Med Health Care Philos 2007;10:129e40.
41. Rose N. The politics of life itself. Theory Cult Soc 2001;18:1e30.
42. Rose N. The politics of life itself: biomedicine, power, and subjectivity in the twenty-first century. Princeton, NJ: Princeton University Press, 2007.